Feel Therapeutics Secures $3.5M in Seed Funding for Groundbreaking Digital Precision Medicine Solutions

Feel Therapeutics, a pioneering Digital Precision Medicine company, is excited to announce it has successfully raised $3.5 million in its latest funding round. This significant investment comes from an impressive lineup of top-tier investors, including Felicis, Anthemis, and SOSV. With this new capital, Feel Therapeutics is poised to expand its innovative approach in reinventing the diagnosis, management, and care for mental health. The funding will be used to enhance its development of novel digital biomarkers and advance its digital health solutions, which can function as standalone therapeutics (DTx) or synergistically alongside traditional medications. By leveraging objective data and passive monitoring, Feel Therapeutics is dedicated to transforming how mental healthcare is delivered, making it more personalized and effective. Their unique focus on combining technology and clinical insights enables the company to lead the charge in developing solutions that address the evolving needs of patients and healthcare providers alike. As mental health continues to be a critical area of concern, Feel Therapeutics is committed to bridging the gap between objective measures and subjective experiences, thereby improving outcomes for those affected by mental health conditions. For more information on how Feel Therapeutics is revolutionizing mental healthcare, please visit our website at www.feeltherapeutics.com or reach out to us at info@feeltherapeutics.com.